This research report looks into the FDA’s ongoing attempts to control 7-hydroxymitraginine (7-OH), which is a naturally occurring alkaloid found in Kratom and is also produced in the human body. We delve into pharmacological literature, expert opinions, and some inconsistencies in regulations to argue that the FDA’s actions show a deeper problem with evidence-based policies. Their focus seems more about protecting established pharmaceutical interests than ensuring public safety. What we aim for is immediate regulatory reform, integrity in journalism, and stronger public scrutiny.
Introduction
In early 2025, a subtle investigation began regarding Kratom regulation. Researchers and advocacy groups started to see troubling trends, particularly an uptick in negative media coverage of 7-OH. This surge wasn’t based on new findings but rather on press releases and coordinated narratives pushed by corporate lobbying.
Central to this situation is 7-OH, a natural byproduct of mitraginine, Kratom’s primary alkaloid. While it has potential benefits for addressing opioid addiction, 7-OH has been unfairly demonized in the FDA’s latest crackdown on alternative substances.
By July 2025, the FDA recommended that 7-OH be classified under the Controlled Substances Act. Concerns cited were vague—ranging from increased consumer product availability to hypothetical risks. However, there was a notable absence of data, such as overdose statistics or peer-reviewed research.
This report is part of a broader investigation into the dynamics at play. It examines who stands to lose from these regulations and who gains economically, highlighting how media, industry, and government often converge on policies that threaten alternative compounds. Consider this a demand for honesty.
Kratom and 7-OH: Scientifically Interconnected
Kratom (Mitragyna speciosa), a tree from Southeast Asia, contains over 40 bioactive alkaloids. The main compound, mitraginine, is metabolized into 7-OH in the liver. Although mitraginine has only mild opioid effects, its conversion to 7-OH enhances the analgesic properties of Kratom.
As some experts suggest, “The discussion on 7-OH should essentially be a discussion on the entire alkaloid profile of Kratom.” Separating the two isn’t scientifically supported.
Yet, despite this biological correlation, regulators and media portray 7-OH as something synthetic, foreign, and dangerous.
Data Does Not Support Panic
Data from the FDA Adverse Event Reporting System (FAERS) remains inadequate and often conflated Kratom with 7-OH. Dr. Michael White, a pharmacologist and FDA advisor, has pointed out these ambiguities.
“There’s no reason for concern about declining reports; any speculation is just that. The dataset isn’t strong enough to form conclusions,” he said.
Paradoxically, this very ambiguity is used to justify prohibition while overlooking decreases in adverse event reporting. Preliminary CDC statistics indicate U.S. opioid-related deaths dropped by 24% from September 2023 to 2024. Notably, during that period, no deaths were directly linked to 7-OH.
Pharmacological Contradictions in FDA Messaging
The FDA’s inconsistent stance on 7-OH reflects a broader pattern of regulatory contradictions. Historically, the agency has reversed its position based on industry pressure, misinterpretations, or political optics.
- In 2016, the DEA attempted to classify Kratom as a Schedule I substance, only to withdraw under public and scientific backlash.
- The FDA has long delayed recognizing the medical use of CBD, even as pharmaceutical companies patented isolated forms like Epidiolex.
- Despite the surge in synthetic opioids like fentanyl, the FDA has primarily targeted natural alternatives.
These inconsistencies reveal a regulatory landscape deeply influenced by market protection rather than genuine public health science. The situation with 7-OH exemplifies this troubling dynamic.
In Continuing Education materials, 7-OH is accurately labeled as a partial opioid agonist, yet, Dr. White mischaracterizes it as a complete opioid agonist. This isn’t just academic; it affects how the public and policymakers view risks and the urgency of scheduling.
Comparison Table: Kratom vs. 7-OH
| Property | Kratom (Leaf) | 7-OH (Separate) |
| Primary Alkaloids | Mitraginine | 7-Hydroxymitraginine |
| Opioid Receptor Activity | Partial agonist by conversion | High affinity partial agonist |
| Start and Duration | Slow onset, long-lasting | Fast onset, short duration |
| Risk of Abuse | Low to Medium | Higher when concentrated |
| Legal Status | Legal in most states | Under FDA Scheduling Review |
Regulatory Capture Cases
It’s worth noting that many popular Kratom brands have been selling products containing 7-OH for years without appropriate regulation. This isn’t a novel compound; it naturally occurs from mitragynine and is part of concentrated Kratom extracts, regardless of label claims.
Brands like OPMS and MIT45 have established multi-million dollar revenues based on advanced Kratom shots that are metabolized into 7-OH. These products, available at convenience stores, lack proper lab testing and disclosures.
As smaller companies produce GMP-compliant isolated 7-OH, legacy brands are pushing for its ban—likely to eliminate what they can’t control. The goal may not genuinely center on consumer safety but rather on market dominance.
The Role of Media Involvement
Over 90% of national media platforms echo FDA press releases with hardly any independent insight. Few journalists dig into the science or seek counterarguments, leaving a narrative that presents 7-OH as a solely harmful substance.
Following the money might reveal who’s truly benefiting, raising questions about whose interests are aligned with maintaining the current system. What results is less journalism and more a failure of institutional integrity.
What the FDA Recommendations Actually Say
The recommendations made by the FDA in July 2025 emphasize:
- Lack of approved medical applications
- Targeting youth
- Inconsistent labeling and dosages
What’s notably absent from the discussion:
- Evidence linking deaths to 7-OH
- Data supporting public health risks
- Clinical trials to explore treatment possibilities
A Smarter, Safer Alternative
If 7-OH were manufactured under GMP standards, it could offer:
- Standardized administration
- Predictable pharmacokinetics
- Potential for harm reduction in opioid transitions
Instead, the FDA’s ban has pushed 7-OH into unregulated markets.
Call to Action: Science, Not Strategy
We request:
- A moratorium on the scheduling of 7-OH, with public hearings and reviews.
- Transparency regarding pharmacological evidence and conflicts of interest influencing FDA decisions.
- Independent clinical trials to assess 7-OH’s safety and efficacy for harm reduction.
- Media accountability, ensuring journalists adhere to scientific and editorial standards rather than simply repeating federal statements.
Conclusion
The discourse surrounding 7-OH highlights a broader failure in integrity, science, regulation, and journalism. Naturally occurring substances, often misunderstood, are preemptively classified based on political and economic pressures rather than real risks.
Public health strategies must be data-driven, transparent, and not swayed by lobbying tactics. It’s crucial that such policies accommodate harm reduction without prematurely limiting opportunities for research and development.
This is a call for vigilance. For resistance. For the truth. The conflict surrounding 7-OH isn’t merely about its nature, but what it symbolizes: a challenge to established norms.
